What drove BMY's revenue growth in Q2 2024?

Bristol-Myers Squibb's (BMY) revenue growth in Q2 2024 was primarily driven by the following factors: 1. **Growth Portfolio Performance**: The company's Growth Portfolio, which includes innovative drugs like Reblozyl and Breyanzi, contributed significantly to the revenue growth. These products showed an 18% increase in revenues, reaching $5.8 billion. 2. **Strong Demand for Key Products**: Specific products such as Reblozyl and Breyanzi exhibited strong demand, which positively impacted the overall revenue. For instance, Reblozyl, approved by the FDA in 2023, is the first and only therapy demonstrating superiority over existing treatments for anemia in myelodysplastic syndromes (MDS). Breyanzi, a CAR-T cell therapy, has also seen increased sales due to expanded manufacturing capacity and recognition as a best-in-class CD19-targeted therapy. 3. **International and Domestic Market Expansion**: The company's U.S. revenues increased by 7% to $8.5 billion, primarily driven by Eliquis, Reblozyl, and Opdualag, with partial offset from Revlimid. International revenues remained relatively flat at $3.4 billion, primarily due to lower average net selling prices, offset in part by higher demand for Opdivo, Yervoy, and Reblozyl. The negative impact from foreign exchange was 5%. In summary, BMY's revenue growth in Q2 2024 was driven by the robust performance of its Growth Portfolio, particularly the strong demand for innovative drugs like Reblozyl and Breyanzi, along with market expansion in both international and domestic fronts.